Iron Depletion Therapy for Type 2 DM and NAFLD

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 2 to Not applicable
    • Study arms: 0 to 1
    v13
  2. Re-verified, no change to tracked fieldsv12
  3. Trial status: Active, Not Recruiting to Completedv11
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v10
  5. Primary and study completion dates: Feb 2009 to Jun 2010v9
Show 7 earlier versionsHide 7 earlier versions
  1. Re-verified, no change to tracked fieldsv8
  2. Study completion date: Oct 2008 to Feb 2009v7
  3. Primary completion date: Feb 2009
    • Study completion date: Oct 2007 to Oct 2008
    • Interventions: iron depletion by phlebotomy (Procedure) to blood donation (Procedure)
    • Secondary endpoints: details revised at 3 of 3 entries
    v6
  4. 2 versions Re-verified since Mar 1, 2007, no change to tracked fieldsv4-v5
  5. Primary endpoints: 3 to 2
    • Secondary endpoints: 4 to 3
    v3
  6. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to find out whether lowering the amount of iron in the body will result in less resistance to insulin and improved liver function in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. This may result in better diabetes control and/or a decrease in the amount of liver fat.
Trial Details
NCT Number NCT00230087
Lead Sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus
Related terms Diabetes Mellitus, Non-alcoholic Fatty Liver Disease
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov